CSPC Pharmaceutical Group Dionica

CSPC Pharmaceutical Group AAQS 2024

CSPC Pharmaceutical Group AAQS

10

Ticker

1093.HK

ISIN

HK1093012172

WKN

548183

CSPC Pharmaceutical Group ima trenutni AAQS od 10. Visoki AAQS može se smatrati pozitivnim pokazateljem da se poduzeće uspješno razvija. Investitori mogu očekivati da je poduzeće na dobrom putu da ostvaruje dobit. S druge strane, važno je usporediti AAQS dionice CSPC Pharmaceutical Group s ostvarenim dobitima i drugim poduzećima iste industrije. Visoki AAQS nije apsolutna garancija za pozitivnu budućnost. Samo tako možemo dobiti potpunu sliku o performansi poduzeća. Da bi bolje procijenili razvoj poduzeća, važno je usporediti AAQS s drugim poduzećima iste industrije. Generalno, investitori bi uvijek trebali razmatrati AAQS poduzeća u kontekstu s drugim financijskim pokazateljima poput dobiti, EBIT-a, Cash Flow-a i drugih kako bi donijeli obrazloženu investicijsku odluku.

CSPC Pharmaceutical Group Aktienanalyse

Što radi CSPC Pharmaceutical Group?

CSPC Pharmaceutical Group Ltd. is a leading pharmaceutical company in China. It was founded in 1997 and specializes in the manufacturing of pharmaceutical raw materials, intermediates, and finished drugs. The company's product range covers various therapy areas and provides a variety of medications for patients worldwide. The company's business model is based on research, development, and production of pharmaceutical products for the mass market. In 2019, CSPC Pharmaceutical achieved a revenue of 9.9 billion USD. The company's products are represented in 24 countries worldwide and aim to improve people's lives through innovations in the healthcare sector. CSPC Pharmaceutical has various divisions, including its sister company CSPC Zhongqi Pharmaceutical Technology Co. Ltd., which specializes in innovative technologies for drug manufacturing. Other divisions include CSPC Weisheng Pharmaceutical Co. Ltd. for marketing and distribution in China, as well as CSPC Ouyi Pharmaceutical Co. Ltd. for the production of traditional Chinese medicines. The product range of CSPC Pharmaceutical is diverse and offers medications for various application areas. This includes cancer therapy with products such as Anastrozole tablets and Vinorelbine injection solution. In the field of cardiovascular diseases, CSPC Pharmaceutical offers Metoprolol Succinate tablets. Additionally, the company provides products for the treatment of pain and inflammation, such as Ibuprofen suspension and generic versions of Celecoxib. Another focus of the company is the research and production of antibiotics, which are important medications in the treatment of bacterial infections. CSPC Pharmaceutical produces a wide range of antibiotics in different dosage forms, including Cefazolin Sodium injection solutions and Cefalotin Sodium injection solutions. Throughout its history, CSPC Pharmaceutical has received various awards and certifications that confirm the high quality of its products. In 2019, the company was honored as the "Best Innovative Pharmaceutical Firm" at the Asia-Pacific Biotech Industry Awards. Furthermore, CSPC Pharmaceutical has obtained the ISO 9001:2015 Quality Management System certificate, and its products are approved by the US FDA, the European Medicines Agency, and the National Medical Products Administration in China. Overall, CSPC Pharmaceutical is an important player in the Chinese pharmaceutical market, offering a wide product range and increasing the level of innovation through research and development. With its continuous growth and efforts towards quality and innovation, CSPC Pharmaceutical will continue to play a significant role in the global healthcare market. CSPC Pharmaceutical Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Česta pitanja o CSPC Pharmaceutical Group dionici

Aktiensparpläne nude atraktivnu mogućnost za investitore za dugoročno stvaranje imovine. Jedna od glavnih prednosti je tzv. efekt prosječenja troškova: investirajući redovito fiksni iznos u dionice ili dioničke fondove, automatski se kupuje više udjela kada su cijene niske, a manje kada su visoke. To može dovesti do povoljnijeg prosječnog cijene po udjelu tijekom vremena. Osim toga, Aktiensparpläne omogućavaju i malim investitorima pristup skupim dionicama, jer mogu sudjelovati već s malim iznosima. Redovita investicija također promiče discipliniranu strategiju ulaganja i pomaže izbjeći emocionalne odluke, poput impulzivne kupnje ili prodaje. Pored toga, investitori profitiraju od potencijalnog povećanja vrijednosti dionica kao i od isplata dividendi koje mogu biti reinvestirane, što pojačava učinak kamatnog kamata i time rast uloženog kapitala.

Andere Kennzahlen von CSPC Pharmaceutical Group

Naša analiza dionica CSPC Pharmaceutical Group Prihod uključuje važne financijske pokazatelje kao što su prihod, dobit, P/E omjer, P/S omjer, EBIT, kao i informacije o dividendi. Također, razmatramo aspekte poput dionica, tržišne kapitalizacije, dugova, vlastitog kapitala i obveza CSPC Pharmaceutical Group Prihod. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama nudimo opsežne analize: